Registry Search

ASBRON

Comprehensive clinical and safety monograph for ASBRON (ASBRON).

ASCLERA

Comprehensive clinical and safety monograph for ASCLERA (ASCLERA).

ASCOR

Comprehensive clinical and safety monograph for ASCOR (ASCOR).

ASCORBIC ACID

Comprehensive clinical and safety monograph for ASCORBIC ACID (ASCORBIC ACID).

ASENAPINE MALEATE

Strong CYP1A2 inhibitors like fluvoxamine increase asenapine levels Sublingual administration food and drink can decrease absorption May cause cerebrovascular events in elderly patients with dementia.

ASENDIN

Comprehensive clinical and safety monograph for ASENDIN (ASENDIN).

ASHLYNA

Comprehensive clinical and safety monograph for ASHLYNA (ASHLYNA).

ASMANEX HFA

Comprehensive clinical and safety monograph for ASMANEX HFA (ASMANEX HFA).

ASMANEX TWISTHALER

Comprehensive clinical and safety monograph for ASMANEX TWISTHALER (ASMANEX TWISTHALER).

ASPARLAS

Comprehensive clinical and safety monograph for ASPARLAS (ASPARLAS).

Aspirin

Aspirin has a profoundly dose-dependent safety and indication profile in pregnancy that mandates clear clinical distinction between low-dose (75–100 mg/day, antiplatelet) and high-dose (≥325 mg, analgesic/anti-inflammatory) use. Low-dose aspirin (LDA) is a cornerstone intervention in obstetric medicine: ACOG, USPSTF (Grade B recommendation), WHO, NICE, and FIGO all recommend initiating LDA at 12–16 weeks gestation (optimally before 16 weeks, ideally by 12 weeks) in women at increased risk of preeclampsia, reducing its incidence by approximately 10–24% overall and by up to 62% when initiated before 16 weeks in high-risk women (ASPRE trial). LDA is also used for antiphospholipid syndrome (APS), prevention of recurrent pregnancy loss in APS, and thromboprophylaxis in specific haematological conditions. High-dose aspirin functions as a full NSAID and carries the class risks of premature closure of the ductus arteriosus (particularly after 20 weeks, critically so after 32 weeks), fetal renal impairment, oligohydramnios, inhibition of labour, and maternal and fetal haemostatic compromise. High-dose aspirin should be avoided after 20 weeks of gestation and is contraindicated after 32 weeks. The FDA issued a Drug Safety Communication in 2020 strengthening warnings against NSAID use (including high-dose aspirin) from 20 weeks onwards.

ASPIRIN AND DIPYRIDAMOLE

Theophylline may antagonize the antiplatelet effect Can cause angina pectoris and hypotension in patients with coronary artery disease.

ASPIRIN; OMEPRAZOLE

Can reduce absorption of drugs requiring gastric pH for absorption (eg ketoconazole) May increase risk of Clostridium difficile-associated diarrhea and bone fractures with long-term use.

ASPRUZYO SPRINKLE

Comprehensive clinical and safety monograph for ASPRUZYO SPRINKLE (ASPRUZYO SPRINKLE).

ASTAGRAF XL

Comprehensive clinical and safety monograph for ASTAGRAF XL (ASTAGRAF XL).

ASTELIN

Comprehensive clinical and safety monograph for ASTELIN (ASTELIN).

ASTEPRO

Comprehensive clinical and safety monograph for ASTEPRO (ASTEPRO).

ASTEPRO ALLERGY

Comprehensive clinical and safety monograph for ASTEPRO ALLERGY (ASTEPRO ALLERGY).

ASTRAMORPH PF

Comprehensive clinical and safety monograph for ASTRAMORPH PF (ASTRAMORPH PF).

ATACAND

Comprehensive clinical and safety monograph for ATACAND (ATACAND).

ATACAND HCT

Comprehensive clinical and safety monograph for ATACAND HCT (ATACAND HCT).

ATARAX

Comprehensive clinical and safety monograph for ATARAX (ATARAX).

ATAZANAVIR SULFATE

Comprehensive clinical and safety monograph for ATAZANAVIR SULFATE (ATAZANAVIR SULFATE).

ATAZANAVIR SULFATE; RITONAVIR

A strong inhibitor of CYP3A4 affecting many drugs Can cause GI intolerance hepatotoxicity and pancreatitis.

ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

ATELVIA

Comprehensive clinical and safety monograph for ATELVIA (ATELVIA).

ATENOLOL

Calcium channel blockers like verapamil may cause bradycardia and heart failure Abrupt withdrawal may exacerbate angina pectoris or cause myocardial infarction.

ATENOLOL AND CHLORTHALIDONE

Other antihypertensive drugs can have additive effects Lithium levels may be increased Can cause hypokalemia and hyponatremia.

ATHENTIA NEXT

Comprehensive clinical and safety monograph for ATHENTIA NEXT (ATHENTIA NEXT).

ATHROMBIN

Comprehensive clinical and safety monograph for ATHROMBIN (ATHROMBIN).

ATHROMBIN-K

Comprehensive clinical and safety monograph for ATHROMBIN-K (ATHROMBIN-K).

ATIVAN

Comprehensive clinical and safety monograph for ATIVAN (ATIVAN).

ATMEKSI

Comprehensive clinical and safety monograph for ATMEKSI (ATMEKSI).

ATNAA

Comprehensive clinical and safety monograph for ATNAA (ATNAA).

ATOMOXETINE HYDROCHLORIDE

Comprehensive clinical and safety monograph for ATOMOXETINE HYDROCHLORIDE (ATOMOXETINE HYDROCHLORIDE).

ATONCY

Comprehensive clinical and safety monograph for ATONCY (ATONCY).

ATORVALIQ

Comprehensive clinical and safety monograph for ATORVALIQ (ATORVALIQ).

ATORVASTATIN CALCIUM

Comprehensive clinical and safety monograph for ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM).

ATOVAQUONE

Metoclopramide and rifampin reduce plasma concentrations Should not be used for serious Pneumocystis pneumonia (PCP) in patients who cannot take it with food.

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Metoclopramide and rifampin reduce plasma concentrations Should not be used for serious Pneumocystis pneumonia (PCP) in patients who cannot take it with food.

ATRACURIUM BESYLATE

Comprehensive clinical and safety monograph for ATRACURIUM BESYLATE (ATRACURIUM BESYLATE).

ATRACURIUM BESYLATE PRESERVATIVE FREE

Comprehensive clinical and safety monograph for ATRACURIUM BESYLATE PRESERVATIVE FREE (ATRACURIUM BESYLATE PRESERVATIVE FREE).

ATRALIN

Comprehensive clinical and safety monograph for ATRALIN (ATRALIN).

ATRIDOX

Comprehensive clinical and safety monograph for ATRIDOX (ATRIDOX).

ATRIPLA

Comprehensive clinical and safety monograph for ATRIPLA (ATRIPLA).

ATROMID-S

Comprehensive clinical and safety monograph for ATROMID-S (ATROMID-S).

ATROPEN

Comprehensive clinical and safety monograph for ATROPEN (ATROPEN).

ATROPINE

Comprehensive clinical and safety monograph for ATROPINE (ATROPINE).

ATROPINE (AUTOINJECTOR)

Comprehensive clinical and safety monograph for ATROPINE (AUTOINJECTOR) (ATROPINE (AUTOINJECTOR)).

ATROPINE AND DEMEROL

Comprehensive clinical and safety monograph for ATROPINE AND DEMEROL (ATROPINE AND DEMEROL).